Mink Therapeutics Inc
INKT11.590USD
+0.060+0.52%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
53.32MMarket Cap
LossP/E TTM
More Details of Mink Therapeutics Inc Company
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
Mink Therapeutics Inc Info
Ticker SymbolINKT
Company nameMink Therapeutics Inc
IPO dateOct 15, 2021
CEOBuell (Jennifer S)
Number of employees23
Security typeOrdinary Share
Fiscal year-endOct 15
Address149 Fifth Avenue
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10010
Phone12129948250
Websitehttps://www.minktherapeutics.com
Ticker SymbolINKT
IPO dateOct 15, 2021
CEOBuell (Jennifer S)
Company Executives of Mink Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
45.58K
+3.67%
Mr. Peter Behner
Mr. Peter Behner
Independent Director
Independent Director
16.17K
+9.97%
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Treasurer
Treasurer
5.79K
-0.03%
Dr. Robert Peter Kadlec
Dr. Robert Peter Kadlec
Independent Director
Independent Director
4.08K
+42.62%
Dr. John B. Holcomb, M.D.
Dr. John B. Holcomb, M.D.
Director
Director
--
--
Ms. Barbara A. Ryan
Ms. Barbara A. Ryan
Independent Director
Independent Director
--
--
Mr. Ulf Wiinberg
Mr. Ulf Wiinberg
Independent Director
Independent Director
--
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Chairman of the Board, Co-Founder
Chairman of the Board, Co-Founder
--
--
Dr. Jennifer S. Buell, Ph.D.
Dr. Jennifer S. Buell, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
45.58K
+3.67%
Mr. Peter Behner
Mr. Peter Behner
Independent Director
Independent Director
16.17K
+9.97%
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Treasurer
Treasurer
5.79K
-0.03%
Dr. Robert Peter Kadlec
Dr. Robert Peter Kadlec
Independent Director
Independent Director
4.08K
+42.62%
Dr. John B. Holcomb, M.D.
Dr. John B. Holcomb, M.D.
Director
Director
--
--
Ms. Barbara A. Ryan
Ms. Barbara A. Ryan
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Agenus, Inc.
46.38%
GKCC, LLC
9.88%
Armen (Garo H.)
3.68%
Corvese (Brian J)
0.97%
Wiinberg Ulf
0.95%
Other
38.13%
Shareholders
Shareholders
Proportion
Agenus, Inc.
46.38%
GKCC, LLC
9.88%
Armen (Garo H.)
3.68%
Corvese (Brian J)
0.97%
Wiinberg Ulf
0.95%
Other
38.13%
Shareholder Types
Shareholders
Proportion
Corporation
56.27%
Individual Investor
7.42%
Investment Advisor
1.27%
Hedge Fund
0.33%
Investment Advisor/Hedge Fund
0.28%
Bank and Trust
0.06%
Research Firm
0.01%
Other
34.37%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
71
71.53K
1.58%
-37.34K
2025Q2
88
3.03M
75.95%
-65.75K
2025Q1
107
3.03M
76.58%
+390.87K
2024Q4
131
3.04M
76.69%
+396.34K
2024Q3
131
3.04M
85.20%
+395.71K
2024Q2
129
3.03M
85.14%
+401.11K
2024Q1
136
2.57M
74.44%
-190.35K
2023Q4
138
2.59M
75.13%
-171.74K
2023Q3
135
2.64M
76.59%
-82.52K
2023Q2
134
2.62M
76.26%
-469.41K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Agenus, Inc.
2.18M
48.14%
--
--
Apr 24, 2025
GKCC, LLC
464.00K
10.26%
--
--
Apr 24, 2025
Armen (Garo H.)
172.80K
3.82%
-1.00
-0.00%
Apr 24, 2025
Corvese (Brian J)
43.97K
0.97%
+1.29K
+3.02%
Sep 02, 2025
Wiinberg Ulf
43.16K
0.95%
+1.01K
+2.40%
Sep 02, 2025
Buell (Jennifer)
36.49K
0.81%
+12.88K
+54.54%
Sep 09, 2025
The Vanguard Group, Inc.
23.74K
0.53%
--
--
Jun 30, 2025
Ryan (Barbara A.)
16.77K
0.37%
+1.28K
+8.27%
Sep 02, 2025
Longbow Finance SA
16.67K
0.37%
--
--
Jun 30, 2025
Behner (Peter)
14.70K
0.33%
+1.17K
+8.67%
Sep 02, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jan 21, 2025
Merger
10→1
Jan 21, 2025
Merger
10→1
Jan 21, 2025
Merger
10→1
Jan 21, 2025
Merger
10→1
Date
Type
Ratio
Jan 21, 2025
Merger
10→1
Jan 21, 2025
Merger
10→1
Jan 21, 2025
Merger
10→1
Jan 21, 2025
Merger
10→1
FAQs
Who are the top five shareholders of Mink Therapeutics Inc?
The top five shareholders of Mink Therapeutics Inc are:
Agenus, Inc. holds 2.18M shares, accounting for 48.14% of the total shares.
GKCC, LLC holds 464.00K shares, accounting for 10.26% of the total shares.
Armen (Garo H.) holds 172.80K shares, accounting for 3.82% of the total shares.
Corvese (Brian J) holds 43.97K shares, accounting for 0.97% of the total shares.
Wiinberg Ulf holds 43.16K shares, accounting for 0.95% of the total shares.
Agenus, Inc. holds 2.18M shares, accounting for 48.14% of the total shares.
GKCC, LLC holds 464.00K shares, accounting for 10.26% of the total shares.
Armen (Garo H.) holds 172.80K shares, accounting for 3.82% of the total shares.
Corvese (Brian J) holds 43.97K shares, accounting for 0.97% of the total shares.
Wiinberg Ulf holds 43.16K shares, accounting for 0.95% of the total shares.
What are the top three shareholder types of Mink Therapeutics Inc?
The top three shareholder types of Mink Therapeutics Inc are:
Agenus, Inc.
GKCC, LLC
Armen (Garo H.)
Agenus, Inc.
GKCC, LLC
Armen (Garo H.)
How many institutions hold shares of Mink Therapeutics Inc (INKT)?
As of 2025Q3, 71 institutions hold shares of Mink Therapeutics Inc, with a combined market value of approximately 71.53K, accounting for 1.58% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -74.37%.
What is the biggest source of revenue for Mink Therapeutics Inc?
In FY2020, the -- business generated the highest revenue for Mink Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
